XJPX4892
Market cap22mUSD
Jan 07, Last price
446.00JPY
1D
-0.45%
1Q
-22.97%
IPO
-79.86%
Name
Cyfuse Biomedical KK
Chart & Performance
Profile
Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was incorporated in 2010 and is based in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY |
---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
Income | ||||
Revenues | 61,112 -83.68% | 374,477 -47.13% | ||
Cost of revenue | 749,368 | 781,982 | ||
Unusual Expense (Income) | ||||
NOPBT | (688,256) | (407,505) | ||
NOPBT Margin | ||||
Operating Taxes | 3,024 | 2,009 | ||
Tax Rate | ||||
NOPAT | (691,280) | (409,514) | ||
Net income | (589,211) 24.32% | (473,962) -431.66% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 22,880 | 2,328,247 | ||
BB yield | -0.38% | -67.09% | ||
Debt | ||||
Debt current | 549,000 | 545,144 | ||
Long-term debt | 345,000 | 363,000 | ||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | (2,979,783) | (3,584,163) | ||
Cash flow | ||||
Cash from operating activities | (562,296) | (403,596) | ||
CAPEX | (19,474) | (228,276) | ||
Cash from investing activities | (19,474) | (430,674) | ||
Cash from financing activities | 18,236 | 2,658,538 | ||
FCF | (648,592) | (571,211) | ||
Balance | ||||
Cash | 3,873,773 | 4,437,307 | ||
Long term investments | 10 | 55,000 | ||
Excess cash | 3,870,727 | 4,473,583 | ||
Stockholders' equity | (702,605) | (124,131) | ||
Invested Capital | 4,819,075 | 4,772,946 | ||
ROIC | ||||
ROCE | ||||
EV | ||||
Common stock shares outstanding | 7,812 | 2,668 | ||
Price | 762.00 -41.43% | 1,301.00 | ||
Market cap | 5,952,919 71.53% | 3,470,566 | ||
EV | 2,973,136 | (113,597) | ||
EBITDA | (650,134) | (353,220) | ||
EV/EBITDA | 0.32 | |||
Interest | 9,774 | 27,934 | ||
Interest/NOPBT |